A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

Inside the tumor: p53 modulates calcium homeostasis

(2015) Carlotta Giorgi et al.   CELL CYCLE

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

(2015) Jan Krönke et al.   NATURE

p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner

(2015) Carlotta Giorgi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

(2014) Y. X. Zhu et al.   BLOOD

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

(2014) L. Saft et al.   HAEMATOLOGICA

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

(2014) Marcus Järås et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

An MDS xenograft model utilizing a patient-derived cell line

(2013) G W Rhyasen et al.   LEUKEMIA

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Regulated Expression of pH Sensing G Protein-Coupled Receptor-68 Identified through Chemical Biology Defines a New Drug Target for Ischemic Heart Disease

(2012) Jamie L. Russell et al.   ACS Chemical Biology

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

(2012) J. Fang et al.   BLOOD

NetWalker: a contextual network analysis tool for functional genomics

(2012) Kakajan Komurov et al.   BMC GENOMICS

Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited

(2012) Andres Jerez et al.   JOURNAL OF CLINICAL ONCOLOGY

ENCODE Data in the UCSC Genome Browser: year 5 update

(2012) Kate R. Rosenbloom et al.   NUCLEIC ACIDS RESEARCH

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

(2012) S Wei et al.   ONCOGENE

The application and biology of immunomodulatory drugs (IMiDs) in cancer

(2012) Beiqing Pan et al.   PHARMACOLOGY & THERAPEUTICS

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

(2012) Aristoteles A.N. Giagounidis   SEMINARS IN HEMATOLOGY

Impact of genetic insights into calpain biology

(2011) Hiroyuki Sorimachi et al.   JOURNAL OF BIOCHEMISTRY

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis

(2010) A Matsuoka et al.   LEUKEMIA

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Extracellular Acidification Elicits Spatially and Temporally Distinct Ca 2+ Signals

(2008) Wan-Chen Huang et al.   CURRENT BIOLOGY

Metabolic Acidosis Increases Intracellular Calcium in Bone Cells Through Activation of the Proton Receptor OGR1

(2008) Kevin K Frick et al.   JOURNAL OF BONE AND MINERAL RESEARCH

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

(2008) Benjamin L Ebert et al.   PLOS MEDICINE